Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug604 | COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection Wiki | 0.63 |
drug683 | Cannabis, Medical Wiki | 0.45 |
drug603 | COVID-19 Swab Wiki | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
drug1091 | EEG Wiki | 0.45 |
drug2659 | Pulse oximetry Wiki | 0.45 |
drug1103 | EP Wiki | 0.45 |
drug656 | CT-scan Wiki | 0.45 |
drug3857 | lung ultrasound Wiki | 0.32 |
drug485 | Blood tests Wiki | 0.32 |
drug1304 | Follow up Wiki | 0.32 |
drug600 | COVID-19 RT-PCR Wiki | 0.26 |
drug376 | BNT162b1 Wiki | 0.26 |
drug377 | BNT162b2 Wiki | 0.22 |
drug2448 | Placebo Wiki | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
D001927 | Brain Diseases NIH | 1.00 |
D020196 | Trauma, Nervous System NIH | 0.45 |
D000070627 | Chronic Traumatic Encephalopathy NIH | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
D009421 | Nervous System Malformations NIH | 0.45 |
D005879 | Tourette Syndrome NIH | 0.45 |
D003424 | Crohn Disease NIH | 0.45 |
D003693 | Delirium NIH | 0.40 |
D005356 | Fibromyalgia NIH | 0.32 |
D000070642 | Brain Injuries, Traumatic NIH | 0.32 |
D000690 | Amyotrophic Lateral Sclerosis NIH | 0.32 |
D012640 | Seizures NIH | 0.32 |
D000013 | Congenital Abnormalities NIH | 0.32 |
D016472 | Motor Neuron Disease NIH | 0.32 |
D006526 | Hepatitis C NIH | 0.32 |
D001714 | Bipolar Disorder NIH | 0.32 |
D000755 | Anemia, Sickle Cell NIH | 0.22 |
D001930 | Brain Injuries, NIH | 0.20 |
D010300 | Parkinsonian NIH | 0.18 |
D009103 | Multiple Sclerosis NIH | 0.17 |
D015212 | Inflammatory Bowel Diseases NIH | 0.17 |
D012598 | Scoliosi NIH | 0.16 |
D059350 | Chronic Pain NIH | 0.15 |
D016638 | Critical Illness NIH | 0.11 |
D004194 | Disease NIH | 0.09 |
D040921 | Stress Disorders, Traumatic NIH | 0.09 |
D013313 | Stress Disorders, Post-Traumatic NIH | 0.08 |
D014947 | Wounds and Injuries NIH | 0.08 |
D013577 | Syndrome NIH | 0.04 |
D003141 | Communicable Diseases NIH | 0.03 |
D007239 | Infection NIH | 0.02 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
D018352 | Coronavirus Infections NIH | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0000707 | Abnormality of the nervous system HPO | 0.45 |
HP:0100280 | Crohn's disease HPO | 0.45 |
HP:0006802 | Abnormal anterior horn cell morphology HPO | 0.32 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100754 | Mania HPO | 0.32 |
HP:0007354 | Amyotrophic lateral sclerosis HPO | 0.32 |
HP:0001250 | Seizure HPO | 0.26 |
HP:0002037 | Inflammation of the large intestine HPO | 0.17 |
HP:0012532 | Chronic pain HPO | 0.15 |
Navigate: Correlations HPO
There are 5 clinical trials
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (https://coronavirus.jhu.edu).
Measure: Prevention of COVID-19 Time: Five yearsDescription: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (https://covid.joinzoe.com/us-2).
Measure: Treatment of COVID-19 Time: Five yearsDescription: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.
Measure: Treatment of Symptoms Time: Five yearsDescription: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.
Measure: Cannabis Impact on Quality of Life Time: Five yearsDescription: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.
Measure: Cannabis Route and Dosing Time: Five yearsDescription: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.
Measure: Monitoring Adverse Events Time: Five yearsInfection with SARS-CoV-2 or severe acute respiratory syndrome coronarvirus type 2 was highlighted in December 2019 in the city of Wuhan in China, responsible for an pandemic evolution since March 11, 2020. The infection affects all ages of life, although affecting children in a very small proportion of cases. The typical presentation of the disease combines fever (98%), cough (76%), myalgia and asthenia (18%) as well as leukopenia (25%) and lymphopenia (63%). Upper airway involvement rare. The main clinical presentation requiring hospitalization of infected patients is that of atypical pneumonia which may require critical care management (27%), and progress to an acute respiratory distress syndrome (67%) involving life-threatening conditions in almost 25% of patients diagnosed with SARS-CoV-2 infection. Other organ damage have been reported, mainly concerning kidney damage (29%) which may require renal replacement therapy in approximately 17% of patients. Neurological damage has been very rarely studied, yet reported in 36% of cases in a study including patients of varying severity. Finally, the mortality associated with this emerging virus is high in patients for whom critical care management is necessary, reported in 62% of patients. We therefore propose a prospective observational study which aim at reporting the prevalence of acute encephalopathy at initial management in Critical/Intensive care or Neurocritical care , to report its morbidity and mortality and to identify prognostic factors.
Description: ratio of patients with acute encephalopathy among the total of patients with SARS-Cov-2 infection at Critical/Intensive care or Neurocritical care admission
Measure: prevalence Time: at Critical/Intensive care or Neurocritical care admissionDescription: A favorable outcome is defined by a Glasgow Outcome Scale (GOS) of 5. The Glasgow Outcome Scale (GOS) will be determined patients charts review, phone call, and/or general practitioner interview conducted by an independent assessor. The GOS score : [1: Death, 2: Persistent vegetative state, 3: Severe disability, 4: Moderate disability, 5 : Low disability]
Measure: Favorable outcome Time: 3 monthsDescription: A favorable outcome is defined by a Glasgow Outcome Scale Extended (GOSe) >= 5. The Glasgow Outcome Scale Extended (GOSe) will be determined patients charts review, phone call, and/or general practitioner interview conducted by an independent assessor. The GOSe score : [1: Death, 2: Persistent vegetative state, 3: Severe disability Lower, 4: Severe disability Upper, 5: Moderate disability Lower, 6: Moderate disability Upper, 7 : Good recovery lower, 8 : Good recovery Upper]
Measure: Favorable outcome Time: 3 monthsDelirium and acute neurocognitive impairment are increasingly observed in adult and pediatric patients with COVID-19. Prospective clinical studies combining clinical and laboratory examinations including specific biomarkers of neuroaxonal injury were not performed for COVID-19. The value of biomarkers of neuroaxonal injury was proven in preliminary studies. These biomarkers could thus contribute to the systematic detection of neurocognitive impairment in patients with COVID-19. Due to worldwide increasing numbers of hospitalized patients with COVID-19, biomarkers of neuroaxonal injury are highly valuable to detect and monitor cognitive impairment, especially with regard to limited resources available to perform time-consuming brain imaging. Biomarkers of neuroaxonal injury are therefore not only of great interest to detect neurocognitive impairment but also to quantify the severity of brain injury in patients with COVID-19.
Description: Assessment of neurocognitive impairment using validated tools
Measure: Incidence of delirium/neurocognitive impairment in adult and pediatric patients with COVID-19 compared to patients without COVID-19 Time: Day 90Description: Measurement of biomarker levels (e.g. NSE, S100B, neurofilament proteins) derived from blood samples
Measure: Change in neuroaxonal injury biomarker levels in patients with COVID-19 compared to patients without COVID-19 Time: Change from baseline biomarker levels at day 28Description: Assessment of the neurocognitive performance of patients using validated tests (e.g. Short Blessed Test)
Measure: Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19 Time: Day 90Description: Assessment of the change in the neurocognitive performance of patients using validated tests (e.g. IQCODE)
Measure: Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19 Time: Change from baseline IQCODE results at day 90Description: Assessment of the overall quality of life using validated tests [e.g. Modified Rankin Scale with a range from 0 (no symptoms) to 6 (dead)]
Measure: Quality of life in patients with COVID-19 compared to patients without COVID-19 after hospital discharge Time: Day 90Description: Cumulative days in hospital
Measure: Length of hospital stay in patients with COVID-19 compared to patients without COVID-19 Time: 1 yearDescription: Survival after 90 days
Measure: 90-day survival in patients with COVID-19 compared to patients without COVID-19 Time: Day 90The SARS-CoV-2 infection was detected in December 2019 in Wuhan City, China. The infection affects all age groups, although childhood is the lowest proportion of those affected. The main clinical manifestations that require hospitalization of infected patients are SARS pneumonia, which may require treatment in the intensive care unit (27%) and its progression into acute respiratory distress syndrome (67%) with life-threatening conditions in almost 25% of patients diagnosed with "SARS-CoV-2 infection". Nervous system damage with SARS-CoV-2 infection has been practically not investigated, but neurological disorders have been reported in 36% of these patients. Finally, the mortality rate associated with the new virus is high in patients who require treatment in intensive care units (62% of cases). Therefore, we are conducting a prospective study to identify acute encephalopathy predictors in patients with COVID-19.
Description: The percentage of patients who have developed encephalopathy
Measure: The percentage of patients who have developed encephalopathy Time: 10 daysThe SARS-CoV-2 epidemic is leading to a large number of patients in intensive care units due to severe hypoxemic pneumonia. After an acute phase that may require controlled mechanical ventilation and deep sedation, removal of sedation often reveals a pathological awakening in the vast majority of patients. This encephalopathy state remains, to date and to our knowledge, unexplained. Clinical features do not appear to fully correlate with regular delirium. This encephalopathy might be explained by deep and prolonged hypoxemia, a wide use of sedation drugs, systemic inflammation or the hostile ICU environment.
Description: Plasminogen activator inhibitor-1 (PAI-1), E-selectin and angiopoietin-2
Measure: Dosage of biomarkers typically explored in intensive care unit delirium Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every 2 daysDescription: S100 β, Neuron Specific Enolase (NSE), GFAP, UCHL1, NFL
Measure: Dosage of neuronal injury markers Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every 2 daysDescription: CAM-ICU (Confusion Assessment Method - Intensive Care Unit) scale
Measure: Delirium assessment Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: ICDSC (Intensive Care Delirium Screening Checklist) scale.
Measure: Delirium assessment Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: CRS-R (Coma Recovery Scale-Revised)
Measure: Coma assessment Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: Clinical observation
Measure: Pupils characteristics Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: Pupilometer assessment
Measure: Pupils characteristics Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: Electroencephalogram : epileptic activity (spikes, spike-waves) or encephalopathy activity (triphasic waves))
Measure: Neurological abnormalities Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: CT-scan
Measure: Neurological abnormalities Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: MRI
Measure: Neurological abnormalities Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports